论文部分内容阅读
目的探讨莫西沙星联合痰热清注射液治疗伴有吸入性危险因素的社区获得性肺炎的临床疗效。方法选取2013年7月—2015年7月蚌埠医学院第一附属医院收治的伴有吸入性危险因素的社区获得性肺炎患者96例,采用随机数字表法分为对照组和观察组,每组48例。对照组患者给予莫西沙星静脉滴注,观察组给予莫西沙星联合痰热清注射液静脉滴注;两组患者均持续治疗3周。比较两组患者临床疗效和临床症状消失时间。结果观察组患者临床疗效优于对照组(P<0.05)。观察组患者发热、咳嗽、咳痰、气促消失时间均短于对照组(P<0.05)。结论莫西沙星联合痰热清注射液治疗伴有吸入性危险因素的社区获得性肺炎的临床疗效确切,有助于改善患者临床症状。
Objective To investigate the clinical efficacy of moxifloxacin combined with Tanreqing Injection in the treatment of community-acquired pneumonia with inhalation risk factors. Methods From July 2013 to July 2015, 96 patients with community-acquired pneumonia with inhalation risk factors admitted to the First Affiliated Hospital of Bengbu Medical College were divided into control group and observation group by random number table, and each group 48 cases. Patients in the control group were given moxifloxacin intravenously, while those in the observation group were given moxifloxacin combined with phlegm-heat injection. The patients in both groups were treated continuously for 3 weeks. The clinical efficacy and the disappearance of clinical symptoms in both groups were compared. Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). The observation group patients fever, cough, expectoration, disappearance of shortness of breath were shorter than the control group (P <0.05). Conclusion The clinical efficacy of moxifloxacin combined with Tanreqing Injection for the treatment of community-acquired pneumonia with inhalation risk factors is definite and helps to improve the clinical symptoms of patients.